The University of Sheffield

Groundbreaking TOURIST Trial Aims to Transform Stage IV Lung Cancer Treatment Through Advanced Radiotherapy

3 months ago

• A pioneering clinical trial called TOURIST is launching to investigate how advanced radiotherapy could extend and improve quality of life for Stage IV lung cancer patients. • The innovative study aims to recruit nearly 1,000 participants with Stage IV lung cancer, accepting patients regardless of age or underlying health conditions, making it uniquely inclusive. • With lung cancer causing 1.2 million deaths worldwide annually, this Christie-sponsored and NIHR-funded trial could potentially revolutionize treatment standards for advanced lung cancer patients.

Durvalumab Immunotherapy Shows Promise in Muscle-Invasive Bladder Cancer Treatment

4 months ago

• A Phase 3 clinical trial reveals that durvalumab, combined with chemotherapy and surgery, significantly reduces cancer recurrence in bladder cancer patients. • The study, involving 1,063 patients, found a 32% reduction in disease progression or recurrence with the addition of durvalumab to standard treatment. • Two-year overall survival rates were notably higher in the durvalumab group (82.2%) compared to the chemotherapy and surgery alone group (75.2%). • Experts hope durvalumab will soon become the new standard of care for muscle-invasive bladder cancer, pending regulatory approval.

Global Trial Aims to Improve Outcomes for Stage IV Non-Small Cell Lung Cancer

8 months ago

• The TOURIST trial, the world's largest of its kind, is recruiting nearly 1,000 patients with stage IV non-small cell lung cancer (NSCLC) to assess the benefits of radiotherapy. • The trial, sponsored by The Christie NHS Foundation Trust, seeks to improve quality of life, reduce symptoms, and extend life expectancy for patients with advanced NSCLC. • Researchers will evaluate if modern radiotherapy techniques, combined with standard treatments, can provide additional benefits to patients with advanced NSCLC. • NSCLC accounts for 85-90% of all lung cancer cases, with approximately half of patients diagnosed at stage IV, highlighting the urgent need for improved treatment strategies.